SVB Leerink - More M&A Deals = Better Exit Ops?

I've pretty much established that I'd like to do healthcare IB after a stint at a boutique, so just wanted to see what people think of Leerink's exit ops into PE/GE. I know before they were pretty much ECM deals with M&A scattered around. But saw that they did the Dicerna sale to Novo Nordisk, Xeris Biopharma, BioIQ etc. So looks like more M&A deals recently while keeping up the ECM volume. 

Would you be able to exit to MM/UMM HC PE/GE? Believe there are a couple threads on their reputation, but not much on the above. Thanks!

10 Comments
 
Most Helpful

What part of Healthcare do you want to work in?

I'd make a strong argument Jeff HC is best for anyone looking for HC services PE/GE (a lot of LBO experience, HC service companies trying to grow fast).

If you're talking about life sciences exits to VC/HF, yeah - I'd agree SVB Leerink is up there.

HCIT - variable since a lot of PE deal flow are tech PE/GE (Veritas for example does a lot in healthcare IT, seen a MTS Health Partners analyst exit there).

 

I'd agree with this. Biopharma M&A isn't relevant for traditional PE, you could maybe LBO a spec pharma or generic company but not very common.

Leerink sends a lot of their guys to growth equity/HFs, the ECM work suffices for people in biopharma so long as they get an understanding of the science.

I'll also second that Jefferies has a good services team and exit ops. The services exits at Leerink should be good given they brought over much of Citi and Guggenheims team.

 

Repellendus est possimus minus. Ullam nihil earum tenetur minima aut. Excepturi maxime consectetur error non.

Et quia alias est laudantium dolores magni voluptatibus fugiat. Qui quia quisquam voluptatem dolores animi soluta. Magnam quibusdam ut voluptatibus natus omnis. Repellendus excepturi quo nam molestias excepturi. Enim facere ratione cumque ab rem.

Laudantium et totam ad et quia dolore. Iure aut enim deleniti minus adipisci. Laudantium earum nostrum unde. A aliquid quas dolores. Qui eligendi sapiente magnam aspernatur explicabo qui similique. Quasi labore harum sed dolorem consequatur aut enim consectetur. Vero odit ut voluptatum dolores dolorem quas.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 07 97.9%
  • Goldman Sachs 02 97.4%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.4%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (53) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
dosk17's picture
dosk17
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”